An observational study in SARS-CoV-2 Acute Respiratory Disease, sponsored by QIAGEN Gaithersburg, Inc. Terminated at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19 infection. This study will evaluate the NeuMoDx SARS-CoV-2 Assay's clinical performance on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems.
QIAGEN Gaithersburg, Inc is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
First submitted after QIAGEN Gaithersburg, Inc became part of QIAGEN.
Counted across the registry records on this site, refreshed daily.
Symptomatic subjects suspected of COVID-19
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prospective specimens, fresh (Category I) shall be tested within:
Exclusion Criteria:
The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.
Sensitivity as compared to the comparator method
Sensitivity ≥ 95% with a lower bound of the two-sided 95% CI \> 90%
Time frame: Through study completion estimated 9 months
Specificity
Specificity ≥ 95% with a lower bound of the two-sided 95% CI \> 90%
Time frame: Through study completion estimated 9 months
Ran from Feb 2024 to primary completion in Jul 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.